Ben Richardson, CEO at SulNOx, confident they can cost-effectively decarbonise commercial shipping. Watch the video here.
Glad to see the back of them. Hopefully the rest follow.
GL
Strict management of resources. The company estimates there is sufficient cash reserves until end of
2024, which could be a value inflexion point from several projects.
In June 2023, it listed on the OTCQB Venture Market in the US, to promote its innovative solutions
and technologies to new investors and add potential liquidity.
Summary
• Cash resources for existing projects are well managed with two funded for up to 3 years.
• The portfolio is to be expanded further with non- dilutive Research Grants for 70% - 80% of
R&D cost of new projects.
• The European Medicine Agency is currently providing program guidance on the lead
treatment.
• NASH clinical trials in humans are scheduled to begin in 2025.
• FDA Regulation is being sought for US trials which could lead to a big Pharma development
partner.
Comment:
There are four longevity treatment programmes progressing with the potential for all to achieve value
added milestones. The company estimated there is sufficient working capital funding to take the more
advanced NASH program to human proof-of-concept stage which is a very significant value inflection
genflow biosciences plc*
progress made with expanding pipeline and winning grants.
founded in 2020, genf is one of the few uk listed companies focused
on longevity biotech discovery to increase human life spans with
better health. it listed in january 2022, raising £3.7m (before
expenses) at 8p a share with an additional cir. £5.4m (€6.3m) in
research grants to develop gene therapies. these are designed to
****** the aging process and to reduce the incidence of age-related
diseases. it owns and is developing proprietary technology for new
therapeutic approaches and treatments with patents pending on
unique drug treatments and delivery systems. its headquarters are in
the uk with r&d facilities in belgium and a new us office in
washington.
opportunity
genf are on a quest to understand and alleviate the impact of ageing
which is a growing market opportunity being driven by demographic
change of an aging population and as people live longer, they wish to
enjoy better health. as longevity gene therapy treatments are
discovered they will become mainstream and no longer characterized
as expensive stem-cells treatments for the super-rich. genf are in the
front of this longevity biotech trend, which will inevitably become an
investment priority for big pharma.
clinical pipeline/ time frame
the development strategy is to gain non-dilutive research grants
which will usually be for around 70 to 80% of the agreed programmes
development costs. to this end genf has a dedicated team processing
verified and costed research programs. the timeline from grant
application to receiving the cash can be hard to predict but genf’s
longevity focus is attracting attention and funds. four research grants
totaling £5.4m have already been won with other applications, to
expedite specific phases of planned research and development, in the
pipeline. the two latest grants were from the government of wallonia
in belgium and the funding will be disbursed annually, contingent
achieving specific, activity-based milestones.
key point. new projects will only be undertaken with grant funding.
the structured grant application process increases the chances of
success as well as broadening genf’s longevity therapies pipeline.
as a larger portfolio of projects are progressed, value is built, the
scientific risk reduces and interest from big parma increases.
key technology
genf believes that a key to human longevity can be found in the genes of centenarians as the ageing
process is genetically influenced caused by dna (cell) damage – which can be repaired using a variant
of the sirt6 gene. the variant of sirt6 gene is found only in centenarians. these centenarians not
only live over 100 years but also rarely suffer from common age-related diseases.
genf is already conducting in-vivo evaluations of its leading centenarian sirt6 gene therapy in four
different nash mice models in conjunction with four leading partners in the field, whe
Great to see a buzz again after a long period of no news! Eric is a genius
A lot of ramping from Earl. Calm down please
Huge RNS!! Well done to everyone
Totally agree! We needs the RNS now
So much huge game changing news that’s due. Also mention of a new program in the Guardian newspaper the other week.
This share is incredibly undervalued!
Evening Money.
I can’t take the credit for that. Someone else found it.
All very promising. Hopefully now the news can drop.
GLA
Partners:
University of Liège | Free University of Brussels - LME | ULG -CORD | CER Group | Revatis | GenFlow Biosciences | QUALITY ASSISTANCE S.A. | UNIVERCELLS | Kaneka Belgium NV | Eurogentec | UCB | BIOPHARMA | Henogen S.A. | UCLouvain - Catholic University of Leuven (TRAIL) - @PILAB | UCL - IMCN/BSMA | UCL -IREC | ULB-BCTL | LiveDrop | salamanderU | PDC*line Pharma | Orgenesis Belgium | DNAlytics | CELYNTRA THERAPEUTICS | OncoDNA | PharmaLex | UCL -LFEM | ULB -CMMI | UMONS - CMMI | XOMEXBIO | Vésale Bioscience | NOVADIP Biosciences S.A. | EXOBIOLOGIC | CYLIX GROUP |
just been posted on telegram! genf mentioned
*************c/1547827892/1748
as part of the wallonia recovery plan, the walloon government is launching an innovation partnership dedicated to atmps (innovative therapy drugs) with a budget of €81 million - 60% public money and 40% private business funds - over 3 years, in collaboration with the biowin cluster - the health cluster of wallonia and the public service of wallonia.
🔬 the partnership involves 26 partners and aims to maintain leadership and strengthen the sector in wallonia by establishing new collaborations between academic partners, a research centre and companies of all sizes.
💊 advanced therapy drugs are new generation biomedicines aimed at meeting unmet medical needs (breast and colorectal cancer, solid tumours, liver fibrosis, central nervous system pathologies...). they represent one of the most innovative and promising revolutions in modern medicine.
👩🏻🔬👨🏼🔬it is estimated that more than 470 direct and 1,200 indirect jobs will be created in the next five years. the atmp sector in wallonia already represents 6,000 direct and indirect jobs.
the atmp pit is a unique opportunity for the development and growth of a sector of importance for the future of wallonia.
Evening Money!
Great posts as always. As the long wait here continues, I’m sure news will land any day now. For certain. Funding grants and new projects!
GL
Great rise, but this is nothing compared to what is to come!
GLA
Money- it’s about time to on all fronts. Huge appetite for bio companies just now.
GLA
Fantastic read. One day the market will get what we are all about
GLA
I hope it’s a bright new year. Can’t get much worse than this.
GLA
Evening Money,
Fantastic post! Hopefully the paper hands are out soon. Looking forward to a blockbuster 2024 here.
GLA
Let the paper hands leave. Nothing has changed here.
GLA
I had a feeling them sells where buys. Great entry
A truly mouth watering list of potential news flow!